On January 13, 2026, China Biopharmaceuticals (1177. HK) announced that it will fully acquire Hangzhou Hejiya Biopharmaceutical Co., Ltd. (hereinafter referred to as "Hejiya"), an innovative pharmaceutical company in the field of small interfering nucleic acid (siRNA) in China, for a total price of 1.2 billion yuan. Through this acquisition, China Biopharmaceutical has acquired a leading independent technology platform, diversified product pipeline, and professional R&D team in the siRNA field, further enriching the group's pipeline layout in the field of chronic diseases.
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablets
(3)Capsules
(4)Spray
(5)Pill press machine
https://www.achievechem.com/pill-press
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-4-009
Tirzepatide CAS 2023788-19-2
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
We provide tirzepatide powder, please refer to the following website for detailed specifications and product information.
Product:https://www.bloomtechz.com/news/peptides-price-list-of-bloom-tech-85355837.html
Hegia was founded in 2018 and is a pioneering biopharmaceutical company focused on the research and development of sRNA innovative drugs. The R&D team led by Cui Kunyuan has over 20 years of professional experience in the development of small nucleic acid drugs, has obtained more than 50 core patents, and has built an integrated innovative drug development system from target discovery to clinical concept verification (POC). With 6 major liver/external delivery platforms, Hejiya's delivery efficiency and product potential are significantly ahead of the industry level, and it is considered a "dark horse" in the domestic small nucleic acid field
MVIP liver targeting platform: the world's first and currently the only clinically validated sIRNA delivery technology platform that can achieve "one dose per year" long-acting drug delivery. In both in vitro and in vivo models, it has shown superior delivery efficiency and effectiveness compared to existing similar platforms. It is the first siRNA delivery technology platform in China to obtain global patent authorization, and its high efficiency, safety, and long-term effectiveness have been tested in multiple clinical pipelines Proof.
DDP dual target delivery platform: It can synchronously deliver dual target siRNA, achieving a synergistic therapeutic effect of "1+1>2". In the future, by combining different tissue targeting platforms, it can be developed for complex or refractory diseases mediated by multiple targets and mechanisms, which has significant technological disruptive potential.
NSDP Neural Targeting Platform: Prospective layout for delivery in the field of neurological diseases, filling the unmet clinical needs of CNS (central nervous system) and PNS (peripheral nervous system). Starting from 2026, products will enter the clinical stage, helping to expand the pipeline to a wider range of disease areas.
The first patient in Phase I clinical trials to successfully receive siRNA therapy for ALS treated with Ruikang from China and the United States
On January 13, 2026, Zhongmei Ruikang announced that its independently developed innovative siRNA therapy RAG-17 targeting S0D1 mutant amyotrophic lateral sclerosis (ALS, commonly known as "Zhezong syndrome") has completed the first patient administration in phase I clinical trials at the Second Affiliated Hospital of Zhejiang University School of Medicine. This experiment was led by Professor Wu Zhiying, Director of the Medical Genetics Department/Rare Disease Diagnosis and Treatment Center of the hospital.
This multicenter clinical trial is a randomized, double-blind, placebo-controlled study with multiple dose escalation (MAD) aimed at evaluating the safety/tolerability, PK, PD, and preliminary efficacy of intrathecal injection of RAG-17 in ALS subjects with SOD1 gene mutations. The participating institutions in the experiment include Beijing Temple of Heaven Hospital affiliated with Capital Medical University (Professor Wang Yilong's team), Second Affiliated Hospital of Zhejiang University School of Medicine (Professor Wu Zhiying's team),
West China Hospital of Sichuan University (Professor Shang Huifang's team), Union Medical College Hospital affiliated with Fujian Medical University (Professor Zou Tanyu's team), and First Affiliated Hospital of Sun Yat sen University (Professor Zeng Jinsheng's team)
RAG-17 is an innovative siRNA drug independently developed by Zhongmei Ruikang, relying on the company's proprietary SCADm (Intelligent Chemical Assisted Delivery) delivery platform technology.
This drug aims to specifically and efficiently target and silence the mRNA expression of SOD1 gene for the treatment of ALS carrying SOD1 gene mutations. The acquisition of toxic functions caused by mutations in the 5OD1 gene is an important pathogenic factor in familial ALS. By efficiently inhibiting SOD1 gene expression and reducing the production of toxic SOD1 protein, RAG-17 aims to protect neuronal function, thereby delaying or preventing the disease progression of SOD1-ALS